Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.46 |
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.39 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.39 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.39 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.39 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 5/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105467 | 0.97 | KDM5A (0.48) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL11587066 | 0.95 | KDM5A (0.47) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL8204357 | 0.95 | KDM5A (0.47) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL30381417 | 0.92 | KDM5A (0.46) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL6560988 | 0.92 | KDM5A (0.53) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL8988089 | 0.90 | KDM5A (0.52) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL9764186 | 0.88 | KDM5A (0.43) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| SCHEMBL10280891 | 0.85 | TDP1 (0.52) | KDM5AKDM4CALDH1A1ALDH2FFAR3 | |
| Hydrochloric Acid SCHEMBL9078509 | 0.85 | KDM5A (0.49) | KDM5AKDM4CALDH1A1PAOXAKR1B1 | |
| SCHEMBL3200406 | 0.85 | KDM5A (0.53) | KDM5AKDM4CALDH1A1ALDH2FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119499211-A | Preparation method and application of cell membrane bionic polymer nano-drug | 南通市通州区人民医院 | 2025-02-25 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| CN-119499211-A | Preparation method and application of cell membrane bionic polymer nano-drug | 南通市通州区人民医院 | 2025-02-25 | — | — | CN | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| WO-2025012376-A1 | IONIZABLE LIPIDS | ETHERNA IMMUNOTHERAPIES NV (BE) | 2025-01-16 | — | — | WO | disclosed |
| US-20250000797-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2025-01-02 | — | — | US | disclosed |
| EP-3640237-B1 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117486754-A | Lipid compound for delivering therapeutic agent and preparation method and application thereof | 尧唐(上海)生物科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115850289-B | Novel pranoprofen derivative, and pharmaceutical composition and application thereof | 石家庄迪斯凯威医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-4992534-A | Anticarcinogenic agents with better water solubility, low toxicity, absorption and stability | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0394989-A2 | Peptide compounds, process for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4960790-A | ANTITUMOR AGENTS, WATER SOLUBLE | UNIVERSITY OF KANSAS (US) | 1990-10-02 | — | — | US | disclosed |
| US-4946951-A | ANTICARCINOGENIC AND-TUMOR AGENTS; VIRICIDES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| CN-1031536-A | 2 '-'-Deoxy-5-fluorouridine derivatives and its production and application | OTSUKA PHARMA CO LTD (JP) | 1989-03-08 | — | — | CN | disclosed |
| EP-0303269-A2 | 2'-Deoxy-5-fluorouridine derivatives, process for preparing the same and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
| EP-0301873-A2 | 2'-deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0227355-A2 | Prodrugs of rapamycin | THE UNIVERSITY OF KANSAS (US) | 1987-07-01 | — | — | EP | disclosed |
| US-4650803-A | WATER-SOLUBLE ANTITUMOR AGENTS | UNIVERSITY OF KANSAS (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | HDAC3 740/4885HDAC1 1008/4885HDAC2 982/4885 |
| US-20250000797-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | HDAC3 2325/4885HDAC1 2700/4885HDAC2 3116/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | HDAC3 740/4885HDAC1 1008/4885HDAC2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.